Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy
Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc. under the name VERSANT HCV Genotype 2.0, is a line probe assay, for in vitro diagnostic use, designed for the qualitative detection and identification of Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes a and b of genotype 1 in human serum or EDTA plasma samples. Additional subtype information is available in a majority of cases.
“At Fujirebio we have been pioneering molecular testing solutions since the 1990’s with our high quality LiPA platform,” says Christiaan De Wilde, CEO at Fujirebio Europe. “The historical VERSANT HCV Genotype 2.0 Assay (LiPA) served as an efficient aid to personalized HCV therapy, and we are very pleased to maintain the availability of the test, now officially a part of our INNO-LiPA product range. We would like to extend our gratitude to all INNO-LiPA customers for their continued trust.”
About Hepatitis C virus
Hepatitis C virus is one of the leading causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (primary liver cancer), resulting in major global public health concerns. The HCV infection is unevenly distributed worldwide, with variations in prevalence across and within countries.1
Globally, an estimated 50 million people have chronic hepatitis C virus infection, with about 1.0 million new infections occurring per year. WHO estimated that in 2022, approximately 242 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma. Early detection and treatment can prevent serious liver damage and improve long-term health.2
About INNO-LiPA HCV 2.0 Genotyping
INNO-LiPA HCV 2.0 Genotyping products are IVDR-marked. The available* products are:
- INNO-LiPA HCV 2.0 Genotyping <20T,CE> (Cat# 81547)
- INNO-LiPA HCV 2.0 Amp <20T,CE> (Cat# 81548)
- INNO-LiPA HCV 2.0 Control <3T,CE> (Cat# 81549)
- LiRAS® for LiPA HCV v4 <CE> (Cat# 15228)
The assay is available in a size of 20T. The test can be performed manually or automated (on the TENDIGO™ (Cat# 80412) instrument) and is not intended to be used as a screening test for HCV or as a diagnostic test to confirm the presence of HCV.
Visit www.fujirebio.com for more information about this product.
* Please contact Fujirebio for further information about the local availability of the test.
References:
- Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, Razzack AA, Solimando AG, Thompson A, Andrews, K, Enebong Nya G, Ahmad S, Ranaldo R, Cozzolongo R, Shahini E. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg. 2021 Oct-Dec;84(4):637-656. doi: 10.51821/84.4.015. PMID: 34965046.
- https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317463658/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Laserfiche Announces 2025 Run Smarter® Award Winners18.3.2025 15:00:00 CET | Press release
Laserfiche — a leading enterprise platform that helps organizations manage their most critical content and workflows — today announced the winners of the 2025 Laserfiche Run Smarter® Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318932755/en/ The awards honor individuals and organizations that yield exceptional business results using Laserfiche. From a state department that revolutionized how it protects the environment to an insurance agency that leapt into action after a hurricane: The winners enhance productivity, foster innovative processes and improve lives with Laserfiche technology. “These honorees are champions of the employee and customer experience,” said Karl Chan, CEO of Laserfiche. “They are leading their industries in transforming how they work using Laserfiche. We are delighted to celebrate their remarkable achievements.” Congratulations to the 2025 Run Smarter Award winners: Angela Goerner, direct
DDC Announces Strategy to Create Bitcoin Reserves and Appoints Crypto Asset Expert Alex Yang as Strategic Advisor18.3.2025 14:14:00 CET | Press release
Bitcoin reserve to be established with up to 100 BTC injection and premium-priced placement of DDC Class A Ordinary shares at $0.50 to $1.25 per share DDC Enterprise, Ltd. (NYSEAM: DDC), (“DayDayCook,” “DDC,” or the “Company”), a leading multi-brand Asian consumer food company, today announced a transformative initiative to adopt Bitcoin as part of its treasury reserves, alongside an announcement that brings seasoned Web3 and Crypto Assets Management Expert Alex Yang to DDC as Strategic Advisor. An investor group will inject up to 100 BTC in exchange for DDC Class A Ordinary shares at a range of $0.50 to $1.25 per share, representing a 100% to 400% premium to recent trading levels. Strategic Alignment with Institutional Confidence “This partnership is a testament to the shared conviction in DDC’s future and the value of Bitcoin and potentially other crypto currencies as a strategic asset,” said Ms. Norma Chu, Chairwoman and CEO of DDC Enterprise. “This strategic decision to launch a bi
Qualcomm Increases Quarterly Cash Dividend18.3.2025 14:00:00 CET | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that its Board of Directors has approved an increase in the Company’s quarterly cash dividend from $0.85 to $0.89 per share of common stock. This dividend increase will be effective for quarterly dividends payable after March 27, 2025, and will raise the annualized dividend payout to $3.56 per share of common stock. Cristiano Amon, President and CEO of Qualcomm Incorporated, said, “We are pleased to announce an increase in our quarterly dividend. Given our long-term growth expectations we provided at our 2024 Investor Day, we remain committed to returning capital to stockholders through a balanced capital return policy, including a baseline of anti-dilutive stock repurchases, and an annualized dividend target of low- to mid-single-digit percentage growth.” About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years
Corpay Cross-Border Grows in Europe with Launch of Luxembourg Office18.3.2025 13:30:00 CET | Press release
Expansion aims to enhance service offering for institutional clients and bolster European growth through an increased market presence Corpay, Inc.*, (NYSE: CPAY), a global leader in corporate payments, is proud to announce its entry into Luxembourg with the establishment of a new office for its Cross-Border business. As part of Corpay’s ongoing expansion in Europe, this significant move aligns with the company’s strategy to enhance its presence in key financial markets worldwide and supports its growth ambitions in the institutional investor and private funds space. “The new Luxembourg office underscores our commitment to supporting the sophisticated needs of this global client base and enables us to provide a localized solution set for our institutional clients that establish their international investment structures in Luxembourg,” says Andrew Shortreid, SVP, Global Institutional Sales, Corpay Cross-Border Solutions. “Luxembourg’s status as a major financial hub in the EMEA region, w
Novotech Partners with Kyungpook National University Hospital to Strengthen Clinical Trial Capabilities in South Korea18.3.2025 13:05:00 CET | Press release
Novotech, a global leading full-service clinical Contract Research Organization (CRO), and Acrostar, a provider of Site Management Organization (SMO) services have entered into a strategic partnership by signing a Memorandum of Understanding (MOU) with Kyungpook National University Hospital (KNUH). The partnership will support clinical trials across KNUH’s prestigious institutions including the Advanced Clinical Trials Center, the KNUH main campus, and the Chilgok KNUH in South Korea. This collaboration is a key milestone for the advanced clinical trials in South Korea, strategically aligning with the amendments to the Advanced Regenerative Bio Act. This agreement builds upon the recent inauguration of KNUH’s Advanced Clinical Trials Center opened in November last year, marking its first official partnership post-amendment of the Bio Act. The amendments to the Advanced Regenerative Bio Act expanded the scope of advanced regenerative medicine, allowing the use of investigational therapi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom